Skip to main content

Table 1 Clinical characteristics of DLBCL patients according to circEAF2 expression

From: CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Characteristics Low expression High expression P value
N = 51 N = 49
Age    0.8418
 ≤ 60 29 (56.9) 29 (59.2)  
 > 60 22 (43.1) 20 (40.8)  
Sex    0.6873
 Female 21 (41.2) 23 (46.9)  
 Male 30 (58.8) 26 (53.1)  
ECOG    0.0095
 0–1 22 (43.1) 34 (69.4)  
 2–5 29 (56.9) 15 (30.6)  
Ann-Arbor stage    0.0699
 I/II 18 (35.3) 27 (55.1)  
 III/IV 33 (64.7) 22 (44.9)  
Extranodal site    0.1430
 0–1 30 (58.8) 36 (73.5)  
 ≥ 2 21 (41.2) 13 (26.5)  
LDH    0.0152
 Normal 16 (31.4) 28 (57.1)  
 Elevated 35 (68.6) 21 (42.9)  
IPI    0.0029
 0–2 20 (39.2) 34 (69.4)  
 3–5 31 (60.8) 15 (30.6)  
Hansa    0.6723
 Non-GCB 32 (62.7) 33 (68.8)  
 GCB 19 (37.3) 15 (31.3)  
CR    0.0206
 No 18 (35.3) 7 (14.3)  
 Yes 33 (64.7) 42 (85.7)  
  1. Values are reported as N (%) of patients unless indicated otherwise
  2. CR Complete remission, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, LDH Lactic dehydrogenase, GCB Germinal center B-cell
  3. aThe calculation was based on 97 patients with available data